Skip to content
Company Analysis

PROCEPT BioRobotics Corporation PRCT

A comprehensive view of key metrics, scores, and financial health for PROCEPT BioRobotics Corporation

Overview of PROCEPT BioRobotics Corporation

PRCT NGM
Healthcare Medical Devices Small Cap
PROCEPT BioRobotics Corporation (PRCT), is a Small Cap company, in the Medical Devices industry, last closed at $27.13, about 70.9% overvalued vs fair value, -54.0% 1Y return, ranked 674/1110 in sector.
$27.13
3.87%
As of March 13, 2026
Previous close • Vol 90d: 66.6%
52-Week Range
Market Cap
$1.37B
Enterprise Value
$1.13B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for PROCEPT BioRobotics Corporation.

Top Beats

Quick Facts

Website https://www.procept-biorobotic...
HQ San Jose, CA
Employees 756
Fiscal year Dec 31

Next Events

Earnings Apr 23 Estimated

Fair Value Snapshot

Bear Base Bull
$7
$8
$9
Current: $27.13 -71% vs base

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$308.1M
37.2%%
Gross Profit
$196.2M
43.1%%
Operating Income
$-103.9M
-7.5%%
Net Income
$-95.6M
-4.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
108.4%
Excellent

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating PROCEPT BioRobotics Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
53
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
46
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing PRCT's balance between Growth (40.8%), Profitability (28.2%), and Safety (31.0%). Growth 41% Safety 31% Profitability 28%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

75th percentile vs peers
76
Key Signals
Rev Growth YoY 37.2% 85p Revenue CAGR 3Y 60.1% 88p EPS Growth YoY 21.7% 45p
Strengths
  • Rev Growth Yoy in top 20% of peers (37.2%, 85th percentile)
  • Revenue Cagr 3Y in top 20% of peers (60.1%, 88th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Current Ratio in top 20% of peers (6.85, 81th percentile)
  • Quick Ratio in top 20% of peers (5.77, 82th percentile)
Risks

No significant risks identified for this axis.

Profitability

52th percentile vs peers
52
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

57th percentile vs peers
58
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for PROCEPT BioRobotics Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$7.90
- - -
-70.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info